• Cyclosporin (B8309): Reliable Assay Design

  2026-08-13

  This scenario-driven guide explains how Cyclosporin (SKU B8309) can support reproducible studies of T-cell signaling, mitochondrial function, viability, and cytotoxicity. It connects mechanism, concentration selection, controls, interpretation, and vendor evaluation to published evidence and practical laboratory decisions.

• Gepotidacin Workflows for Resistance Research

  2026-08-13

  Build more informative antibacterial assays with Gepotidacin, from MIC testing and topoisomerase biochemistry to resistance profiling. This guide connects mechanism-specific readouts with translational pharmacokinetic considerations for reproducible antibiotic resistance research.

• Dual Recombinase Tracing Finds No Mouse Neo-Oogenesis

  2026-08-13

  Xie, Zhou, and Zheng use orthogonal Cre-loxP and Dre-rox lineage tracing to test whether postnatal mouse ovarian cells generate new oocytes. Across physiological aging and busulfan-induced ovarian injury, no labeled growing oocytes or metaphase II eggs were detected, providing strong in vivo evidence against postnatal neo-oogenesis in mice.

• Fucoidan Workflows for Cancer and Viral Assays

  2026-08-12

  Explore practical Fucoidan workflows for apoptosis, immune activity, angiogenesis, and exploratory herpesvirus nuclear-egress assays. The guide combines product-handling controls with a mechanism-aware strategy for separating cytotoxicity from membrane-fusion effects.

• SAR131675: Mapping VEGFR-3 Across Fibrosis and Cancer

  2026-08-12

  SAR131675 offers a selective pharmacology framework for testing how VEGFC–VEGFR-3 signaling connects lymphangiogenesis, macrophage behavior, fibrosis, and tumor biology. This thought-leadership guide translates its mechanistic evidence into practical study-design guidance while keeping translational maturity and safety limitations in view.

• Cimetidine: A Barrier-Aware Research Framework

  2026-08-11

  Cimetidine is more than a gastric acid secretion inhibitor: its distinctive H2 receptor pharmacology can be studied alongside modern barrier assays. This article provides a decision framework for cancer research, gastrointestinal models, and cautious CNS translation without conflating permeability with efficacy.

• SCH772984 HCl: ERK1/2 Inhibitor Workflow

  2026-08-10

  Build cleaner MAPK experiments with SCH772984 HCl, a nanomolar ERK1/2 inhibitor suited to pathway validation, resistance studies, and mutant cancer models. A practical workflow also shows how to pair ERK readouts with TERT and telomerase assays without overstating an emerging stem-cell connection.

• Mildronate-Derived Lipidoids for Safer mRNA Delivery

  2026-08-09

  The 2024 ACS Nano study developed mLNP-69, a low-dose lipid nanoparticle incorporating mildronate-derived cationic lipids, to preserve mRNA delivery while reducing local inflammation. In prophylactic and therapeutic B16OVA melanoma models, the formulation supported effective cancer vaccine delivery, highlighting a strategy for improving the tolerability of mRNA vaccine systems.

• Phosphatase Inhibitor Cocktail 2: Assay Design

  2026-08-08

  Phosphatase Inhibitor Cocktail 2 supports protein phosphorylation preservation in studies of nucleolar remodeling and proteostasis. This guide focuses on pre-analytical control, assay compatibility, and how to distinguish biological phosphorylation from ex vivo dephosphorylation.

• Metoprolol Tartrate: Designing Selective β1 Assays

  2026-08-07

  Metoprolol Tartrate enables precise β1-adrenergic receptor inhibition in cardiovascular and hematopoietic research. This guide translates recent transplantation findings into practical assay-design decisions for selectivity, formulation, controls, and tissue-specific interpretation.

• Dabigatran Etexilate: Direct Thrombin Inhibition Without CYP

  2026-08-07

  Dabigatran etexilate introduces a major advance in oral anticoagulation by providing rapid and predictable direct thrombin inhibition, independent of CYP3A-mediated metabolism. This innovation reduces drug-drug interaction risk and simplifies therapeutic management for venous thromboembolism and atrial fibrillation, with significant implications for pharmacokinetic and drug-drug interaction research.

• Recombinant Human IL-15: Optimizing T and NK Cell Assays

  2026-08-06

  Leverage Recombinant Human IL-15 for precise, high-yield T and NK cell proliferation assays. This guide details practical workflows, troubleshooting strategies, and protocol enhancements to maximize immune modulation for research, linking neuroimmune insights to robust experimental design.

• Ro 3306: Precision CDK1 Inhibitor for G2/M Phase Arrest

  2026-08-06

  Ro 3306 empowers cancer researchers with highly selective, reversible control of the cell cycle, enabling synchronized G2/M arrest and advanced DNA repair studies. This article details experimental workflows, troubleshooting, and the latest mechanistic insights, unlocking new assay strategies for targeted cell cycle research.

• ECL Western Blotting Substrate: Protocol, QC, and Best Pract

  2026-08-05

  ECL Western Blotting Substrate (SKU K2187) provides a robust, nonradioactive chemiluminescent solution for detecting horseradish peroxidase (HRP) in immunoblots, supporting sensitive protein detection workflows. It should be selected for applications requiring high signal-to-noise detection by chemiluminescence and is not appropriate for fluorescent or radioisotopic assays.

• Hepatic sEH–Nrf2 Axis: A Novel Driver of Osteoclastogenesis

  2026-08-05

  A recent study uncovers how hepatic soluble epoxide hydrolase (sEH) promotes osteoclast differentiation by suppressing the Nrf2 antioxidant pathway, linking liver metabolism with bone resorption in osteoporosis. These findings clarify a liver-bone signaling axis and suggest new angles for redox and signaling pathway modulation in bone disease research.

451 records 8/31 page Previous Next First page 上5页 678910 下5页 Last page